OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
April 02, 2022
3D cell cultures could provide key avenues to unlocking critical information.
Advances in pharmaceutical neuroscience present an opportunity for pharmaceutical companies to stay ahead of the curve.
April 01, 2022
Under the two-year task order, ATCC will continue to support the DCEG MEAS program in receiving, processing, storing, analyzing, and distributing clinical specimens from different cancer types.
March 31, 2022
Sanofi and IGM Biosciences have announced a collaboration agreement for oncology, immunology, and inflammation targets.
March 29, 2022
Orion is planning to refocus its R&D efforts on the development of new proprietary products focused on cancer and pain.
March 25, 2022
Huma has acquired AstraZeneca’s digital health platform, and AstraZeneca has become a shareholder of Huma in a partnership to accelerate digital-first patient care.
DFE Pharma, Harro Höfliger, and Sterling have announced a partnership called Inhalation Together to provide formulation services for respiratory products.
March 24, 2022
Gamma Biosciences has announced an initiative through its subsidiary, Mirus Bio, to develop lipid-polymer nanocomplexes for improve mRNA delivery solutions.
March 21, 2022
physIQ and CellCarta are conducting a study to evaluate individual patient response to vaccination using wearable biosensors.
March 18, 2022
Sanofi is collaborating with Blackstone Life Sciences to accelerate the development of a treatment for multiple myeloma.